•
HA
HALO
Halozyme Therapeutics, Inc.
polygonBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
8.43B
Volume
14.10K
52W High
$79.50
52W Low
$47.50
Open
$71.94
Prev Close
$71.71
Day Range
71.64 - 71.97
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Latest News
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Benzinga•Dec 16
Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look
The Motley Fool•Nov 5
Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025
GlobeNewswire Inc.•Nov 5
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
GlobeNewswire Inc.•Oct 29
Subcutaneous RYBREVANT®▼(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
GlobeNewswire Inc.•Oct 19
RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) reduces acquired resistance versus osimertinib in first-line EGFR-mutated advanced non-small cell lung cancer
GlobeNewswire Inc.•Sep 6
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.•Aug 26
Halozyme (HALO) Q2 EPS Jumps 69%
The Motley Fool•Aug 6